» Articles » PMID: 26157300

Hematocrit As a Simple Method to Predict and Manage Ovarian Hyperstimulation Syndrome in Assisted Reproduction

Overview
Date 2015 Jul 10
PMID 26157300
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The aim was to analyze the hematocrit levels in cases of ovarian hyperstimulation syndrome (OHSS), syndrome occurring during in-vitro fertilization (IVF), and study its role as a prognostic indicator.

Subjects And Methods: Two years data of 66 women at high risk for developing OHSS was analyzed. Twenty-seven women who developed OHSS were further analyzed based on their hematocrit levels on the day of oocyte pick-up (OPU) and the day of embryo transfer (ET) to see if there was a prognostic trend.

Results: Of the total 225 IVF cases, 66 were deemed high risk for developing OHSS. Twenty-seven of these developed OHSS (40.9%). Of these 27, 21 (77.8%) had a hematocrit >35% on the day of OPU. The mean hematocrit in women developing OHSS on the day of OPU was 37.39% (standard deviation [SD] 2.66) as against 35.97% (2.80) in those not developing OHSS. This difference was statistically significant (P = 0.043). On the day of ET, 23/27 (85.8%) who developed OHSS had a hematocrit of >35%. The mean hematocrit was 39.29% (SD 3.85) in those who developed OHSS as against 34.7% (2.88) in those who did not. This difference (4.85) was statistically significant (P < 0.001).

Conclusions: Women undergoing IVF were at a higher risk of developing OHSS when their hematocrit on the day of OPU and ET was >35%. Those who required cancellation of ET had a hematocrit of >35% on the day of ET or showed a significant increase of 3% from OPU to ET.

Citing Articles

High Maternal Neonatal Mortality and Morbidity in Pregnancy with Eisenmenger Syndrome.

Dachlan E, Amirah , Cininta N, Pranadyan R, Putri A, Oktaviono Y J Pregnancy. 2021; 2021:3248850.

PMID: 34616573 PMC: 8490032. DOI: 10.1155/2021/3248850.


The Goto-Kakizaki rat is a spontaneous prototypical rodent model of polycystic ovary syndrome.

Bourgneuf C, Bailbe D, Lamaziere A, Dupont C, Moldes M, Farabos D Nat Commun. 2021; 12(1):1064.

PMID: 33594056 PMC: 7886868. DOI: 10.1038/s41467-021-21308-y.

References
1.
Jayaprakasan K, Jayaprakasan R, Al-Hasie H, Clewes J, Campbell B, Johnson I . Can quantitative three-dimensional power Doppler angiography be used to predict ovarian hyperstimulation syndrome?. Ultrasound Obstet Gynecol. 2009; 33(5):583-91. DOI: 10.1002/uog.6373. View

2.
Delvigne A, Rozenberg S . Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002; 8(6):559-77. DOI: 10.1093/humupd/8.6.559. View

3.
Fiedler K, Ezcurra D . Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol. 2012; 10:32. PMC: 3403873. DOI: 10.1186/1477-7827-10-32. View

4.
Devroey P, Polyzos N, Blockeel C . An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011; 26(10):2593-7. DOI: 10.1093/humrep/der251. View

5.
Kaiser U . The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med. 2003; 349(8):729-32. DOI: 10.1056/NEJMp038106. View